Search

Your search keyword '"Slot, Annerie"' showing total 36 results
Start Over Author "Slot, Annerie" Search Limiters Academic (Peer-Reviewed) Journals
36 results on '"Slot, Annerie"'

1. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Author

Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.

Published
2021
Full Text
View/download PDF

2. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas

Author

Jamieson, Amy, primary, Vermij, Lisa, additional, Kramer, Claire J.H., additional, Jobsen, Jan J., additional, Jürgenliemk-Schulz, Ina, additional, Lutgens, Ludy, additional, Mens, Jan Willem, additional, Haverkort, Marie A.D., additional, Slot, Annerie, additional, Nout, Remi A., additional, Oosting, Jan, additional, Carlson, Joseph, additional, Howitt, Brooke E., additional, Ip, Philip P.C., additional, Lax, Sigurd F., additional, McCluggage, W. Glenn, additional, Singh, Naveena, additional, McAlpine, Jessica N., additional, Creutzberg, Carien L., additional, Horeweg, Nanda, additional, Gilks, C. Blake, additional, and Bosse, Tjalling, additional

Published
2023
Full Text
View/download PDF

3. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas

Author

Jamieson, Amy, Vermij, Lisa, Kramer, Claire J.H., Jobsen, Jan J., Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A.D., Slot, Annerie, Nout, Remi A., Oosting, Jan, Carlson, Joseph, Howitt, Brooke E., Ip, Philip P.C., Lax, Sigurd F., McCluggage, W. Glenn, Singh, Naveena, McAlpine, Jessica N., Creutzberg, Carien L., Horeweg, Nanda, Gilks, C. Blake, Bosse, Tjalling, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J.H., Jobsen, Jan J., Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A.D., Slot, Annerie, Nout, Remi A., Oosting, Jan, Carlson, Joseph, Howitt, Brooke E., Ip, Philip P.C., Lax, Sigurd F., McCluggage, W. Glenn, Singh, Naveena, McAlpine, Jessica N., Creutzberg, Carien L., Horeweg, Nanda, Gilks, C. Blake, and Bosse, Tjalling

Abstract

PURPOSE: The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review pathologic and molecular characteristics, and outcomes of stage I low-grade p53abn EEC in a large international cohort. EXPERIMENTAL DESIGN: Previously diagnosed stage I p53abn EC (POLE-wild-type, mismatch repair-proficient) low-grade EEC from Canadian retrospective cohorts and PORTEC-1&2 trials were included. Pathology review was performed by six expert gynecologic pathologists blinded to p53 status. IHC profiling, next-generation sequencing, and shallow whole-genome sequencing was performed. Kaplan-Meier method was used for survival analysis. RESULTS: We identified 55 stage I p53abn low-grade EEC among 3,387 cases (2.5%). On pathology review, 17 cases (31%) were not diagnosed as low-grade EEC by any pathologists, whereas 26 cases (47%) were diagnosed as low-grade EEC by at least three pathologists. The IHC and molecular profile of the latter cases were consistent with low-grade EEC morphology (ER/PR positivity, patchy p16 expression, PIK3CA and PTEN mutations) but they also showed features of p53abn EC (TP53 mutations, many copy-number alterations). These cases had a clinically relevant risk of disease recurrence (5-year recurrence-free survival 77%), with pelvic and/or distant recurrences observed in 12% of the patients. CONCLUSIONS:A subset of p53abn EC is morphologically low-grade EEC and exhibit genomic instability. Even for stage I disease, p53abn low-grade EEC are at substantial risk of disease recurrence. These findings highlight the clinical relevance of universal p53-testing, even in low-grade EEC, to identify women at increased risk of recurrence.

Published
2023

4. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas

Author

MS Radiotherapie, Cancer, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J H, Jobsen, Jan J, Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A D, Slot, Annerie, Nout, Remi A, Oosting, Jan, Carlson, Joseph, Howitt, Brooke E, Ip, Philip P C, Lax, Sigurd F, McCluggage, W Glenn, Singh, Naveena, McAlpine, Jessica N, Creutzberg, Carien L, Horeweg, Nanda, Gilks, C Blake, Bosse, Tjalling, MS Radiotherapie, Cancer, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J H, Jobsen, Jan J, Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A D, Slot, Annerie, Nout, Remi A, Oosting, Jan, Carlson, Joseph, Howitt, Brooke E, Ip, Philip P C, Lax, Sigurd F, McCluggage, W Glenn, Singh, Naveena, McAlpine, Jessica N, Creutzberg, Carien L, Horeweg, Nanda, Gilks, C Blake, and Bosse, Tjalling

Published
2023

5. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial

Author

de Boer, Stephanie M., Nout, Remi A., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Lutgens, Ludy C.H.W., van der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W., and Creutzberg, Carien L.

Published
2015
Full Text
View/download PDF

6. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.

Author

Horeweg, Nanda, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., Haverkort, Marie A.D., Mens, Jan Willem M., Slot, Annerie, Wortman, Bastiaan G., de Boer, Stephanie M., Stelloo, Ellen, Verhoeven-Adema, Karen W., Putter, Hein, Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., Creutzberg, C.L., Koper, P.C.M., van Putten, W.L.J., and Dercksen, R.

Published
2023
Full Text
View/download PDF

7. 2022-RA-925-ESGO Development of adjuvant treatment decision support tool for endometrial cancer patients by pooled analysis of data from 2000 women included in the PORTEC-1–3 trials and a prospective cohort study

Author

Vermij, Lisa, primary, Putter, Hein, additional, Jobsen, Jan, additional, Powell, Melanie, additional, de Boer, Stephanie, additional, Leary, Alexandra, additional, Bessette, Paul, additional, Mileshkin, Linda, additional, Lutgens, Ludy, additional, Jürgenliemk-Schulz, Ina, additional, Slot, Annerie, additional, van der Steen-Banasik, Elzbieta, additional, Nout, Remi, additional, Smit, Vincent, additional, Steyerberg, Ewout, additional, Creutzberg, Carien, additional, Bosse, Tjalling, additional, and Horeweg, Nanda, additional

Published
2022
Full Text
View/download PDF

8. 2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials

Author

Wakkerman, Famke Charlotte, primary, De Boer, Stephanie M, additional, Powell, Melanie E, additional, Leary, Alexandra, additional, Fyles, Anthony, additional, Mileshkin, Linda R, additional, Singh, Naveena, additional, Nout, Remi A, additional, Jürgenliemk-Schulz, Ina M, additional, Jobsen, Jan J, additional, Lutgens, Ludy CHW, additional, van der Steen-Banasik, Elsbieta M, additional, Mens, Jan-Willem M, additional, Slot, Annerie, additional, Nijman, Hans W, additional, Smit, Vincent THBM, additional, Bosse, Tjalling, additional, Creutzberg, Carien L, additional, and Horeweg, Nanda, additional

Published
2022
Full Text
View/download PDF

9. 2022-RA-450-ESGO Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer

Author

Horeweg, Nanda, primary, Nout, Remi A, additional, Stelloo, Ellen, additional, Lutgens, Ludy CHW, additional, Jobsen, Jan J, additional, Jürgenliemk-Schulz, Ina M, additional, van der Steen-Banasik, Elsbieta M, additional, Mens, Jan-Willem M, additional, Slot, Annerie, additional, Smit, Vincent THBM, additional, Bosse, Tjalling, additional, and Creutzberg, Carien L, additional

Published
2022
Full Text
View/download PDF

11. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data

Author

Nout, Remi A., Putter, Hein, Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Lutgens, Ludy C.H.W., van der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Nijman, Hans W., van de Poll-Franse, Lonneke V., and Creutzberg, Carien L.

Published
2012
Full Text
View/download PDF

12. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer:Implications for shared decision making

Author

Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., Creutzberg, Carien L., Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.

Abstract

Background: Decision making regarding adjuvant therapy for high-risk endometrial cancer is complex. The aim of this study was to determine patients' and clinicians' minimally desired survival benefit to choose chemoradiotherapy over radiotherapy alone. Moreover, influencing factors and importance of positive and negative treatment effects (i.e. attribute) were investigated. Methods: Patients with high-risk endometrial cancer treated with adjuvant pelvic radiotherapy with or without chemotherapy and multidisciplinary gynaecologic oncology clinicians completed a trade-off questionnaire based on PORTEC-3 trial data. Results: In total, 171 patients and 63 clinicians completed the questionnaire. Median minimally desired benefit to make chemoradiotherapy worthwhile was significantly higher for patients versus clinicians (10% vs 5%, p = 0.02). Both patients and clinicians rated survival benefit most important during decision making, followed by long-term symptoms. Older patients (OR 0.92 [95%CI 0.87–0.97]; p = 0.003) with comorbidity (OR 0.34 [95% CI 0.12–0.89]; p = 0.035) had lower preference for chemoradiotherapy, while patients with better numeracy skills (OR 1.2 [95%CI 1.05–1.36], p = 0.011) and chemoradiotherapy history (OR 25.0 [95%CI 8.8–91.7]; p < 0.001) had higher preference for chemoradiotherapy. Conclusions: There is a considerable difference in minimally desired survival benefit of chemoradiotherapy in high-risk endometrial cancer among and between patients and clinicians. Overall, endometrial cancer patients needed higher benefits than clinicians before preferring chemoradiotherapy.

Published
2021

13. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Author

MS Radiotherapie, Cancer, Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., Creutzberg, Carien L., MS Radiotherapie, Cancer, Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.

Published
2021

14. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Author

Heerik, A. van den, Horeweg, N., Nout, R.A., Lutgens, L., Steen-Banasik, E.M. van der, Westerveld, G.H., Berg, H.A. van den, Slot, Annerie, Koppe, F.L.A., Kommoss, S., Mens, J.W.M., Nowee, M.E., Bijmolt, S., Cibula, D., Stam, T.C., Jurgenliemk-Schulz, I.M., Snyers, A., Hamann, Moritz, Zwanenburg, A.G., Coen, V., Vandecasteele, K., Gillham, C., Chargari, C., Verhoeven-Adema, K.W., Putter, H., Hout, W.B. Van den, Wortman, B.G., Nijman, Hans, Bosse, T., Creutzberg, C.L., Heerik, A. van den, Horeweg, N., Nout, R.A., Lutgens, L., Steen-Banasik, E.M. van der, Westerveld, G.H., Berg, H.A. van den, Slot, Annerie, Koppe, F.L.A., Kommoss, S., Mens, J.W.M., Nowee, M.E., Bijmolt, S., Cibula, D., Stam, T.C., Jurgenliemk-Schulz, I.M., Snyers, A., Hamann, Moritz, Zwanenburg, A.G., Coen, V., Vandecasteele, K., Gillham, C., Chargari, C., Verhoeven-Adema, K.W., Putter, H., Hout, W.B. Van den, Wortman, B.G., Nijman, Hans, Bosse, T., and Creutzberg, C.L.

Abstract

Contains fulltext : 229912.pdf (Publisher’s version ) (Open Access), BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life. However, there is still considerable overtreatment and also some undertreatment, which may be reduced by tailoring adjuvant treatment to the patients' risk of recurrence based on molecular tumor characteristics. PRIMARY OBJECTIVES: To compare the rates of vaginal recurrence in women with high-intermediate risk endometrial cancer, treated after surgery with molecular-integrated risk profile-based recommendations for either observation, vaginal brachytherapy or external pelvic beam radiotherapy or with standard adjuvant vaginal brachytherapy STUDY HYPOTHESIS: Adjuvant treatment based on a molecular-integrated risk profile provides similar local control and recurrence-free survival as current standard adjuvant brachytherapy in patients with high-intermediate risk endometrial cancer, while sparing many patients the morbidity of adjuvant treatment and reducing healthcare costs. TRIAL DESIGN: A multicenter, international phase III randomized trial (2:1) of molecular-integrated risk profile-based adjuvant treatment (experimental arm) or adjuvant vaginal brachytherapy (standard arm). MAJOR INCLUSION/EXCLUSION CRITERIA: Women aged 18 years and over with a histological diagnosis of high-intermediate risk endometrioid endometrial cancer after total abdominal or laparoscopic hysterectomy and bilateral salpingo-oophorectomy. High-intermediate risk factors are defined as: (i) International Federation of Gynecology and Obstetrics stage IA (with invasion) and grade 3; (ii) stage IB grade 1 or 2 with age ≥60 and/or lymph-vascular space invasion; (iii) stage IB, grade 3 without lymph-vascular space invasion; or (iv) stage II (microscopic and grade 1). ENDPOINTS: The primary endpoint is vaginal recurrence. Secondary endpoints are recurrence-free a

Published
2020

15. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Author

van den Heerik, Anne Sophie V M, primary, Horeweg, Nanda, additional, Nout, Remi A, additional, Lutgens, Ludy C H W, additional, van der Steen-Banasik, Elzbieta M, additional, Westerveld, G Henrike, additional, van den Berg, Hetty A, additional, Slot, Annerie, additional, Koppe, Friederike L A, additional, Kommoss, Stefan, additional, Mens, Jan Willem M, additional, Nowee, Marlies E, additional, Bijmolt, Stefan, additional, Cibula, David, additional, Stam, Tanja C, additional, Jurgenliemk-Schulz, Ina M, additional, Snyers, An, additional, Hamann, Moritz, additional, Zwanenburg, Aleida G, additional, Coen, Veronique L M A, additional, Vandecasteele, Katrien, additional, Gillham, Charles, additional, Chargari, Cyrus, additional, Verhoeven-Adema, Karen W, additional, Putter, Hein, additional, van den Hout, Wilbert B, additional, Wortman, Bastiaan G, additional, Nijman, Hans W, additional, Bosse, Tjalling, additional, and Creutzberg, Carien L, additional

Published
2020
Full Text
View/download PDF

19. Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.

Author

Bolla, Michel, Neven, Anouk, Maingon, Philippe, Carrie, Christian, Boladeras, Ana, Andreopoulos, Demetrios, Engelen, Antoine, Sundar, Santhanam, van der Steen-Banasik, Elzbieta M, Armstrong, John, Peignaux-Casasnovas, Karine, Boustani, Jihane, Herrera, Fernanda G, Pieters, Bradley R, Slot, Annerie, Bahl, Amit, Scrase, Christopher D, Azria, David, Jansa, Jan, and O'Sullivan, Joe M

Published
2021
Full Text
View/download PDF

21. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial

Author

de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., and Stam, Tanja C.

Subjects
Canada, Time Factors, Endometrial Neoplasms/mortality, Clinical Trial, Phase III, Risk Factors, Paclitaxel/administration & dosage, Journal Article, Humans, Comparative Study, Aged, Neoplasm Staging, Gynecologic Surgical Procedures/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Research Support, Non-U.S. Gov't, Australia, Carboplatin/administration & dosage, Chemoradiotherapy, Adjuvant/adverse effects, Middle Aged, Europe, Multicenter Study, Treatment Outcome, Oncology, Randomized Controlled Trial, Carcinoma, Endometrioid/mortality, Lymph Node Excision, Female, Radiotherapy, Adjuvant, Dose Fractionation, Radiation, Neoplasm Grading, Cisplatin/administration & dosage, New Zealand
Abstract

BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. METHODS: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m 2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m 2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. RESULTS: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1-73·1). 5-year overall survival was 81·8% (95% CI 77·5-86·2) with chemoradiotherapy versus 76·7% (72·1-81·6) with radiotherapy (adjusted hazard ratio [HR] 0·76, 95% CI 0·54-1·06; p=0·11); 5-year failure-free survival was 75·5% (95% CI 70·3-79·9) versus 68·6% (63·1-73·4; HR 0·71, 95% CI 0·53-0·95; p=0·022). Grade 3 or worse adverse events during treatment occurred in 198 (60%) of 330 who received chemoradiotherapy versus 41 (12%) of 330 patients who received radiotherapy (p

Published
2018

22. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients

Author

Voogd, Adri C., Tienhoven, Geertjan van, Peterse, Hans L., Crommelin, Mariad A., Rutgers, Emiel J. Th., Velde, Cornelis van de, Geel, Bert N. van, Slot, Annerie, Rodrigus, Patrick T., Jobsen, Jan J., Meyenfeldt, Maarten F. von, and Coebergh, Jan-Willem W.

Subjects
Breast cancer -- Patient outcomes, Metastasis -- Risk factors, Cancer -- Relapse, Health
Published
1999

23. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Author

MS Radiotherapie, Cancer, de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., Stam, Tanja C., PORTEC study group, MS Radiotherapie, Cancer, de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., Stam, Tanja C., and PORTEC study group

Published
2018

24. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Author

Cats, Annemieke, primary, Jansen, Edwin P M, additional, van Grieken, Nicole C T, additional, Sikorska, Karolina, additional, Lind, Pehr, additional, Nordsmark, Marianne, additional, Meershoek-Klein Kranenbarg, Elma, additional, Boot, Henk, additional, Trip, Anouk K, additional, Swellengrebel, H A Maurits, additional, van Laarhoven, Hanneke W M, additional, Putter, Hein, additional, van Sandick, Johanna W, additional, van Berge Henegouwen, Mark I, additional, Hartgrink, Henk H, additional, van Tinteren, Harm, additional, van de Velde, Cornelis J H, additional, Verheij, Marcel, additional, Van Coevorden, Frits, additional, Vanhoutvin, Steven, additional, Hulshof, Maarten CCM, additional, Loosveld, Olaf JL, additional, Ten Tije, A (Bert) Jan, additional, Erdkamp, Frans LG, additional, Warmerdam, Fabienne ARM, additional, Van der Peet, Donald L, additional, Verheul, Henk MW, additional, Boerma, Djamila, additional, Los, Maartje, additional, Slot, Annerie, additional, Houtsma, Danny, additional, Portielje, Johanna EA, additional, Blaisse, Reinoud JB, additional, Spillenaar Bilgen, Ernst Jan, additional, Polée, Marco B, additional, Geenen, Maud M, additional, Braak, Jeffrey PBM, additional, Neelis, Karen J, additional, Slingerland, Marije, additional, Jansen, Rob LH, additional, Buijsen, Jeroen, additional, Beeker, Aart, additional, Eijsbouts, Quirijn AJ, additional, Van Riel, Johanna MGH, additional, Rozema, Tom, additional, Van Spronsen, Dick Johan, additional, Meerum Terwogt, Jetske M, additional, Tanis, Bea C, additional, Van der Torren-Conze, Adelheid ME, additional, Van Hilligersberg, Richard, additional, Koopman, Miriam, additional, Den Boer, Marien O, additional, Creemers, Geert-Jan, additional, Van der Sangen, Maurice, additional, Rentinck, Marjolein EM, additional, Van den Berg, H Pieter, additional, Jonkers, Ge JPM, additional, Grootenboers, Diane, additional, Vulink, Annelie JE, additional, Hovenga, Sjoerd, additional, Van der Mijle, Huub CJ, additional, Baars, Arnold, additional, Haringhuizen, Annebeth W, additional, Appels, Marije IE, additional, Rietbroek, Ron C, additional, Hendriksen, Ellen M, additional, Legdeur, Marie-Cecile JC, additional, Ten Bokkel Huinink, Daan, additional, Van Dobbenburgh, O Aart, additional, Smit, Jitty M, additional, Van Bochove, Aart, additional, Veldhuis, Gerrit-Jan, additional, Muller, Erik W, additional, Bonenkamp, J (Han) J, additional, Braam, Pètra M, additional, De Boer, Jaap, additional, Van Halteren, Henk K, additional, Valster, Fransje AA, additional, Imholz, Alex LT, additional, Van Dijk, Marjan A, additional, Van der Gaast, Ate, additional, Otten, J (Hans)-Martin MB, additional, Ceha, Heleen M, additional, Glimelius, Bengt, additional, Lagerbäck, Cecillia, additional, Perman, Mats, additional, Johnsson, Anders, additional, Borg, David, additional, Nielsen, Niels H, additional, Piwowar, Andrzej, additional, Elmlund, Mattias, additional, Hörberg, Helene, additional, Edlund, Per, additional, Johansson, Bengt, additional, Flygare, Petra, additional, and Jespersen, Marie Louise, additional

Published
2018
Full Text
View/download PDF

26. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de radiothérapie oncologique, Bolla, Michel, Maingon, Philippe, Carrie, Christian, Villa, Salvador, Kitsios, Petros, Poortmans, Philip M P, Sundar, Santhanam, van der Steen-Banasik, Elzbieta M, Armstrong, John, Bosset, Jean-François, Herrera, Fernanda G, Pieters, Bradley, Slot, Annerie, Bahl, Amit, Ben-Yosef, Rahamim, Boehmer, Dirk, Scrase, Christopher, Renard, Laurette, Shash, Emad, Coens, Corneel, van den Bergh, Alphonsus C M, Collette, Laurence, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de radiothérapie oncologique, Bolla, Michel, Maingon, Philippe, Carrie, Christian, Villa, Salvador, Kitsios, Petros, Poortmans, Philip M P, Sundar, Santhanam, van der Steen-Banasik, Elzbieta M, Armstrong, John, Bosset, Jean-François, Herrera, Fernanda G, Pieters, Bradley, Slot, Annerie, Bahl, Amit, Ben-Yosef, Rahamim, Boehmer, Dirk, Scrase, Christopher, Renard, Laurette, Shash, Emad, Coens, Corneel, van den Bergh, Alphonsus C M, and Collette, Laurence

Abstract

Purpose Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer. Patients and Methods A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) $ 10 ng/mL or Gleason$7, or (2) cT2a (International Union Against Cancer TNM1997),with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA # 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80%power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided a = 5%. Results The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P , .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet. Conclusion Six months of concomitant and adjuvant AS improves biochemical and c

Published
2016

27. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

Author

Bolla, Michel, primary, Maingon, Philippe, additional, Carrie, Christian, additional, Villa, Salvador, additional, Kitsios, Petros, additional, Poortmans, Philip M.P., additional, Sundar, Santhanam, additional, van der Steen-Banasik, Elzbieta M., additional, Armstrong, John, additional, Bosset, Jean-François, additional, Herrera, Fernanda G., additional, Pieters, Bradley, additional, Slot, Annerie, additional, Bahl, Amit, additional, Ben-Yosef, Rahamim, additional, Boehmer, Dirk, additional, Scrase, Christopher, additional, Renard, Laurette, additional, Shash, Emad, additional, Coens, Corneel, additional, van den Bergh, Alphonsus C.M., additional, and Collette, Laurence, additional

Published
2016
Full Text
View/download PDF

28. EORTC trial 22991: Results of a phase III study comparing 6 months of androgen suppression and irradiation versus irradiation alone for localized T1b-cT2aN0M0 prostate cancer.

Author

Bolla, Michel, primary, Van Den Bergh, Alphonsus C.M., additional, Carrie, Christian, additional, Villà, Salvador, additional, Kitsios, Petros, additional, Poortmans, Philip M., additional, Sundar, Santhanam, additional, van der Steen-Banasik, Elzbieta M., additional, Armstrong, John, additional, Bosset, Jean-Francois, additional, Herrera, Fernanda, additional, Pieters, Bradley, additional, Slot, Annerie, additional, Bahl, Amit, additional, Collette, Laurence, additional, and Maingon, Philippe, additional

Published
2016
Full Text
View/download PDF

29. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: Results from the randomized PORTEC-2 trial

Author

MS Radiotherapie, Cancer, De Boer, Stephanie M., Nout, Remi A., Jurgenliemk-Schulz, Ina M., Jobsen, Jan J, Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W, Creutzberg, Carien L., MS Radiotherapie, Cancer, De Boer, Stephanie M., Nout, Remi A., Jurgenliemk-Schulz, Ina M., Jobsen, Jan J, Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W, and Creutzberg, Carien L.

Published
2015

30. Less Gastrointestinal Toxicity After Adjuvant Radiotherapy on a Small Pelvic Field Compared to a Standard Pelvic Field in Patients With Endometrial Carcinoma

Author

de Jong, Renske A., primary, Pras, Elisabeth, additional, Boezen, H. Marike, additional, van der Zee, Ate G.J., additional, Mourits, Marian J.E., additional, Arts, Henriëtte J.G., additional, Aalders, Jan G., additional, Slot, Annerie, additional, Timmer, Paul R., additional, Hollema, Harry, additional, and Nijman, Hans W., additional

Published
2012
Full Text
View/download PDF

31. Target volume delineation variation in radiotherapy for early stage rectal cancer in the Netherlands

Author

Nijkamp, Jasper, primary, de Haas-Kock, Danielle F.M., additional, Beukema, Jannet C., additional, Neelis, Karen J., additional, Woutersen, Dankert, additional, Ceha, Heleen, additional, Rozema, Tom, additional, Slot, Annerie, additional, Vos-Westerman, Hanneke, additional, Intven, Martijn, additional, Spruit, Patty H., additional, van der Linden, Yvette, additional, Geijsen, Debby, additional, Verschueren, Karijn, additional, van Herk, Marcel B., additional, and Marijnen, Corrie A.M., additional

Published
2012
Full Text
View/download PDF

33. The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor

Author

Jobsen, Jan J., primary, ten Cate, Lambert Naudin, additional, Lybeert, Marnix L.M., additional, van der Steen-Banasik, Elzbieta M., additional, Scholten, Astrid, additional, van der Palen, Job, additional, Slot, Annerie, additional, Kroese, Marika C. Stenfert, additional, Schutter, Eltjo M.J., additional, and Siesling, Sabine, additional

Published
2010
Full Text
View/download PDF

34. Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial

Author

Nout, Remi A., primary, Putter, Hein, additional, Jürgenliemk-Schulz, Ina M., additional, Jobsen, Jan J., additional, Lutgens, Ludy C.H.W., additional, van der Steen-Banasik, Elzbieta M., additional, Mens, Jan Willem M., additional, Slot, Annerie, additional, Stenfert Kroese, Marika C., additional, van Bunningen, Bart N.F.M., additional, Smit, Vincent T.H.B.M., additional, Nijman, Hans W., additional, van den Tol, Philine P., additional, and Creutzberg, Carien L., additional

Published
2009
Full Text
View/download PDF

36. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer

Author

Peeters, Stephanie T.H., Lebesque, Joos V., Heemsbergen, Wilma D., van Putten, Wim L.J., Slot, Annerie, Dielwart, Michel F.H., and Koper, Peter C.M.

Subjects
*CANCER treatment, *RADIOTHERAPY, *PROSTATE, *CANCER radiotherapy complications, *CANCER patients, *MEDICAL radiology
Abstract

Purpose: To identify dosimetric parameters derived from anorectal, rectal, and anal wall dose distributions that correlate with different late gastrointestinal (GI) complications after three-dimensional conformal radiotherapy for prostate cancer. Methods and Materials: In this analysis, 641 patients from a randomized trial (68 Gy vs. 78 Gy) were included. Toxicity was scored with adapted Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer (RTOG/EORTC) criteria and five specific complications. The variables derived from dose–volume histogram of anorectal, rectal, and anal wall were as follows: % receiving ≥5–70 Gy (V5–V70), maximum dose (Dmax), and mean dose (Dmean). The anus was defined as the most caudal 3 cm of the anorectum. Statistics were done with multivariate Cox regression models. Median follow-up was 44 months. Results: Anal dosimetric variables were associated with RTOG/EORTC Grade ≥2 (V5–V40, Dmean) and incontinence (V5–V70, Dmean). Bleeding correlated most strongly with anorectal V55–V65, and stool frequency with anorectal V40 and Dmean. Use of steroids was weakly related to anal variables. No volume effect was seen for RTOG/EORTC Grade ≥3 and pain/cramps/tenesmus. Conclusion: Different volume effects were found for various late GI complications. Therefore, to evaluate the risk of late GI toxicity, not only intermediate and high doses to the anorectal wall volume should be taken into account, but also the dose to the anal wall. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results